Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways.
CONCLUSIONS: This case suggests that concurrent genetic polymorphisms can impair multiple apixaban elimination pathways and thus substantially increase its exposure.
PMID: 31464657 [PubMed - in process]
Source: BMC Pharmacology and Toxicology - Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research
More News: Atrial Fibrillation | Bleeding | Brain | Drugs & Pharmacology | Emergency Medicine | Genetics | Hemorrhagic Stroke | Ischemic Stroke | Neurology | Stroke | Toxicology